EQRx, Inc.
NASDAQ: EQRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Melanie I. Nallicheri
- Employees
- 362
- Headquarters
- Cambridge, United States
- IPO year
- 2021
- Market cap
- $1.1B
- Website
- https://www.eqrx.com
Loading EQRX…
Loading profile data…Frequently asked questions about EQRX
What does EQRx, Inc. (EQRX) do?
EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for pat...
Where does EQRX trade?
EQRx, Inc. (EQRX) trades on the NASDAQ Global Market.
What sector is EQRX in?
EQRx, Inc. (EQRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of EQRx, Inc.?
Melanie I. Nallicheri is the chief executive officer of EQRx, Inc. (EQRX).
Where is EQRx, Inc. headquartered?
EQRx, Inc. is headquartered in United States.
Does EQRX pay a dividend?
EQRx, Inc. (EQRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EQRX go public?
EQRx, Inc. (EQRX) completed its initial public offering in 2021.